A New Frontier: PARP Inhibitors Plus Antiandrogens in BRCA- or HRR-Mutated mCRPC
Pharmacy Times,
In 2023, FDA-approved indications for PARP inhibitors in combination with antiandrogens expanded into the metastatic castration-r…
In 2023, FDA-approved indications for PARP inhibitors in combination with antiandrogens expanded into the metastatic castration-r…
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…